+Vote!
Market Wire - Pharmaceuticals and Biotech: Biotech (Free subscription) | 2 hours ago
SOUTH SAN FRANCISCO, CA (MARKET WIRE) Theravance, Inc. (NASDAQ: THRX) reported today its financial results for the quarter ended June 30, 2008. Net loss for the second quarter of 2008 was $27.0 million, compared with $45.1 million for the same period of 2007, a decrease of $18.1 million. Net loss per share was $0.44 for the second quarter 2008 compared with a net loss per share of $0.75 for...
+Vote!
Market Wire - Pharmaceuticals and Biotech: Biotech (Free subscription) | 2 hours ago
SOUTH SAN FRANCISCO, CA (MARKET WIRE) Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that it will report second quarter results on Thursday, July 31, 2008 at 4:00 p.m. Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 p.m. Eastern Time to discuss operational and financial results and the company's outlook for the future.
+Vote!
Inbox Robot: Swiss Reinsurance News (Free subscription) | 07/23/2008
SOUTH SAN FRANCISCO, Calif. & MODESTO, Calif. (Business Wire EON) July 22, 2008 -- In addition to spirited competition and record-breaking performances, California cheeses will be ...
1Vote!
Inbox Robot: Swiss Reinsurance News (Free subscription) | 07/22/2008
(07-21) 10:35 PDT SOUTH SAN FRANCISCO -- Swiss drugmaker Roche stunned executives of Genentech Inc. on Monday with a $43.7 billion offer to ...
+Vote!
NBC11.com - Local News (Free subscription) | 07/23/2008
A 52-year-old South San Francisco man faces charges of assault with a deadly weapon on uniformed peace officers, brandishing a firearm replica and resisting arrest after allegedly attempting to shoot police with a BB gun Monday night.
1Vote!
New York Times (Free subscription) | 07/22/2008
Roche's bid for the rest of Genentech isn't creating anywhere near the hoopla that greeted InBev's offer for Anheuser-Busch. It's understandable: While many consider Genentech, of South San Francisco, the most successful biotech company on the planet, it doesn't quite have the brand recognition of Anheuser, which makes Budweiser beer. But the two bids have [...].
+Vote!
Business Wire (Free subscription) | 07/23/2008
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Scientists at the Scripps Research Institute have uncovered the structure of a critical protein from the Ebola Virus that allows viral entry in
+Vote!
Business Wire (Free subscription) | 07/22/2008
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq:EXEL) will release its second quarter 2008 financial results on Tuesday, August 5, 2008, after the markets close.
1Vote!
Market Wire - Pharmaceuticals and Biotech: Drugs (Free subscription) | 07/22/2008
SOUTH SAN FRANCISCO, CA (MARKET WIRE) Theravance, Inc. (NASDAQ: THRX) announced today that the U.S. Food and Drug Administration (FDA) has not yet made a decision regarding the New Drug Application (NDA) for telavancin. The Prescription Drug User Fee Act (PDUFA) date for action by FDA was July 21, 2008, and as of that date, the company had not received an action letter from the FDA. Telavancin...
+Vote!
Inbox Robot: Swiss Reinsurance News (Free subscription) | 07/21/2008
(07-21) 10:35 PDT SOUTH SAN FRANCISCO -- Swiss drugmaker Roche is offering $43.7 billion to acquire full control of its marketing partner Genentech ...
1Vote!
DealBook (Free subscription) | 07/22/2008
Roche’s bid for the rest of Genentech isn’t creating anywhere near the hoopla that greeted InBev’s offer for Anheuser-Busch. It’s understandable: While many consider Genentech, of South San Francisco, the most successful biotech company on the planet, it doesn’t quite have the brand recognition of Anheuser, which makes Budweiser beer. But the two bids have [...]
+Vote!
Business Wire (Free subscription) | 07/22/2008
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cell Genesys, Inc. (Nasdaq:CEGE) announced today the publication of final data from the second of two Phase 2 clinical trials (G-0010) of GVAX
1Vote!
SFist (Free subscription) | 07/21/2008
South San Francisco biotechnology company Genentech, makers of some of the world's most boring prescription drugs ever (e.g., supplementary growth hormones Protropin and Nutropin , clot-busting pill TNKase , non-Hodgkins lymphomas treatment Rituxan , and zzzzzzz ) might be bought out by Swiss drug company Roche . The European pill-pushers are offering the Bay Area company a whopping $43.7 billion....
